SG/CALL/ELI LILLY & CO/1010/0.1/21.06.24 | Market Closed - Boerse Frankfurt Warrants 20:35:31 09/05/2024 BST | ||
| 0.027 EUR | -12.90% |
|
| Current month | -83.89% | ||
| 1 month | -93.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 0.029 | -6.45% | 0 |
| 08/05/24 | 0.031 | -24.39% | 0 |
| 07/05/24 | 0.041 | +310.00% | 0 |
| 06/05/24 | 0.01 | +900.00% | 0 |
| 03/05/24 | 0.001 | -98.08% | 0 |
Real-time Boerse Frankfurt Warrants
Last update May 09, 2024 at 08:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU997H |
| ISIN | DE000SU997H7 |
| Date issued | 05/03/2024 |
| Strike | 1,010 $ |
| Maturity | 21/06/2024 (43 Days) |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.14 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.113 € |
| Spread % | 86.92% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
775
USD
Average target price
850.4
USD
Spread / Average Target
+9.73%
- Stock Market
- Warrants
- Warrant
